UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
FORM 10-Q |
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) |
Pennsylvania | 23-1210010 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
530 Herman O. West Drive, Exton, PA | 19341-0645 |
(Address of principal executive offices) | (Zip Code) |
Large accelerated filer | þ | Accelerated filer | o | |
Non-accelerated filer | o | (Do not check if a smaller reporting company) | Smaller reporting company | o |
Emerging growth company | o |
Page | ||
FINANCIAL STATEMENTS (UNAUDITED) | ||
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | ||
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | ||
CONTROLS AND PROCEDURES | ||
LEGAL PROCEEDINGS | ||
RISK FACTORS | ||
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | ||
OTHER INFORMATION | ||
EXHIBITS | ||
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Net sales | $ | 387.7 | $ | 362.1 | |||
Cost of goods and services sold | 253.6 | 238.8 | |||||
Gross profit | 134.1 | 123.3 | |||||
Research and development | 10.3 | 9.4 | |||||
Selling, general and administrative expenses | 61.6 | 58.1 | |||||
Other expense (Note 12) | 0.9 | 25.8 | |||||
Operating profit | 61.3 | 30.0 | |||||
Interest expense | 2.1 | 2.5 | |||||
Interest income | 0.3 | 0.3 | |||||
Income before income taxes | 59.5 | 27.8 | |||||
Income tax expense | 2.2 | 6.9 | |||||
Equity in net income of affiliated companies | 3.6 | 1.2 | |||||
Net income | $ | 60.9 | $ | 22.1 | |||
Net income per share: | |||||||
Basic | $ | 0.83 | $ | 0.31 | |||
Diluted | $ | 0.81 | $ | 0.30 | |||
Weighted average shares outstanding: | |||||||
Basic | 73.3 | 72.5 | |||||
Diluted | 74.9 | 74.1 | |||||
Dividends declared per share | $ | 0.13 | $ | 0.12 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Net income | $ | 60.9 | $ | 22.1 | |||
Other comprehensive income (loss), net of tax: | |||||||
Foreign currency translation adjustments | 5.9 | 14.9 | |||||
Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.1) and $0.2 | (0.1 | ) | 0.4 | ||||
Net gain on investment securities, net of tax of $0.1 | 0.3 | — | |||||
Net gain (loss) on derivatives, net of tax of $0.8 and $(0.2) | 1.7 | (0.7 | ) | ||||
Other comprehensive income, net of tax | 7.8 | 14.6 | |||||
Comprehensive income | $ | 68.7 | $ | 36.7 |
March 31, 2017 | December 31, 2016 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 169.4 | $ | 203.0 | |||
Accounts receivable, net | 224.8 | 200.5 | |||||
Inventories | 212.3 | 199.3 | |||||
Other current assets | 46.1 | 39.1 | |||||
Total current assets | 652.6 | 641.9 | |||||
Property, plant and equipment | 1,583.6 | 1,554.7 | |||||
Less: accumulated depreciation and amortization | 800.8 | 776.4 | |||||
Property, plant and equipment, net | 782.8 | 778.3 | |||||
Investments in affiliated companies | 81.3 | 82.7 | |||||
Goodwill | 103.5 | 103.0 | |||||
Deferred income taxes | 68.7 | 66.2 | |||||
Intangible assets, net | 23.1 | 23.3 | |||||
Other noncurrent assets | 21.5 | 21.3 | |||||
Total Assets | $ | 1,733.5 | $ | 1,716.7 | |||
LIABILITIES AND EQUITY | |||||||
Current liabilities: | |||||||
Notes payable and other current debt | $ | 34.4 | $ | 2.4 | |||
Accounts payable | 106.1 | 122.0 | |||||
Pension and other postretirement benefits | 2.3 | 2.2 | |||||
Accrued salaries, wages and benefits | 43.9 | 51.6 | |||||
Income taxes payable | 6.2 | 4.5 | |||||
Other current liabilities | 63.6 | 58.3 | |||||
Total current liabilities | 256.5 | 241.0 | |||||
Long-term debt | 194.2 | 226.2 | |||||
Deferred income taxes | 9.8 | 9.2 | |||||
Pension and other postretirement benefits | 57.1 | 75.6 | |||||
Other long-term liabilities | 47.3 | 47.2 | |||||
Total Liabilities | 564.9 | 599.2 | |||||
Commitments and contingencies (Note 14) | |||||||
Equity: | |||||||
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding | — | — | |||||
Common stock, $0.25 par value; 100.0 million shares authorized; issued: 74.4 million and 73.7 million; outstanding: 73.6 million and 73.1 million | 18.6 | 18.4 | |||||
Capital in excess of par value | 276.0 | 260.4 | |||||
Retained earnings | 1,118.8 | 1,071.6 | |||||
Accumulated other comprehensive loss | (179.0 | ) | (186.8 | ) | |||
Treasury stock, at cost (0.8 million and 0.6 million shares) | (65.8 | ) | (46.1 | ) | |||
Total Equity | 1,168.6 | 1,117.5 | |||||
Total Liabilities and Equity | $ | 1,733.5 | $ | 1,716.7 |
Common Stock | Capital in Excess of Par Value | Treasury Stock | Retained earnings | Accumulated other comprehensive (loss) income | Total | |||||||||||||||||||||
Shares | Amount | |||||||||||||||||||||||||
Balance, December 31, 2016 | 73.7 | $ | 18.4 | $ | 260.4 | $ | (46.1 | ) | $ | 1,071.6 | $ | (186.8 | ) | $ | 1,117.5 | |||||||||||
Effect of modified retrospective application of a new accounting standard (see Note 2) | — | — | — | — | (4.1 | ) | — | (4.1 | ) | |||||||||||||||||
Net income | — | — | — | — | 60.9 | — | 60.9 | |||||||||||||||||||
Stock-based compensation | — | — | (0.7 | ) | 7.5 | — | — | 6.8 | ||||||||||||||||||
Shares issued under stock plans | 0.7 | 0.2 | 16.7 | 3.1 | — | — | 20.0 | |||||||||||||||||||
Shares purchased under share repurchase program | — | — | — | (26.9 | ) | — | — | (26.9 | ) | |||||||||||||||||
Shares repurchased for employee tax withholdings | — | — | (0.4 | ) | (3.4 | ) | — | — | (3.8 | ) | ||||||||||||||||
Dividends declared | — | — | — | — | (9.6 | ) | — | (9.6 | ) | |||||||||||||||||
Other comprehensive income, net of tax | — | — | — | — | — | 7.8 | 7.8 | |||||||||||||||||||
Balance, March 31, 2017 | 74.4 | $ | 18.6 | $ | 276.0 | $ | (65.8 | ) | $ | 1,118.8 | $ | (179.0 | ) | $ | 1,168.6 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Cash flows from operating activities: | |||||||
Net income | $ | 60.9 | $ | 22.1 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Depreciation | 22.6 | 21.6 | |||||
Amortization | 0.7 | 0.7 | |||||
Stock-based compensation | 3.5 | 4.6 | |||||
Non-cash restructuring charges | — | 15.0 | |||||
Other non-cash items, net | (3.2 | ) | (1.0 | ) | |||
Changes in assets and liabilities | (63.8 | ) | (60.0 | ) | |||
Net cash provided by operating activities | 20.7 | 3.0 | |||||
Cash flows from investing activities: | |||||||
Capital expenditures | (37.5 | ) | (39.0 | ) | |||
Other, net | 2.8 | 0.4 | |||||
Net cash used in investing activities | (34.7 | ) | (38.6 | ) | |||
Cash flows from financing activities: | |||||||
Borrowings under revolving credit agreements | — | — | |||||
Repayments under revolving credit agreements | — | — | |||||
Repayments of long-term debt | (0.6 | ) | (68.0 | ) | |||
Dividend payments | (9.5 | ) | (8.7 | ) | |||
Excess tax benefits from employee stock plans | — | 11.0 | |||||
Shares purchased under share repurchase program | (26.9 | ) | (9.1 | ) | |||
Shares repurchased for employee tax withholdings | (3.8 | ) | (3.7 | ) | |||
Proceeds from exercise of stock options and stock appreciation rights | 18.1 | 12.6 | |||||
Employee stock purchase plan contributions | 1.0 | 0.8 | |||||
Contingent consideration payments | (0.1 | ) | — | ||||
Net cash used in financing activities | (21.8 | ) | (65.1 | ) | |||
Effect of exchange rates on cash | 2.2 | 4.2 | |||||
Net decrease in cash and cash equivalents | (33.6 | ) | (96.5 | ) | |||
Cash and cash equivalents at beginning of period | 203.0 | 274.6 | |||||
Cash and cash equivalents at end of period | $ | 169.4 | $ | 178.1 |
Three Months Ended March 31, | |||||||
(In millions) | 2017 | 2016 | |||||
Net income | $ | 60.9 | $ | 22.1 | |||
Weighted average common shares outstanding | 73.3 | 72.5 | |||||
Dilutive effect of equity awards, based on the treasury stock method | 1.6 | 1.6 | |||||
Weighted average shares assuming dilution | 74.9 | 74.1 |
($ in millions) | March 31, 2017 | December 31, 2016 | |||||
Raw materials | $ | 81.7 | $ | 78.0 | |||
Work in process | 33.0 | 28.9 | |||||
Finished goods | 97.6 | 92.4 | |||||
$ | 212.3 | $ | 199.3 |
($ in millions) | March 31, 2017 | December 31, 2016 | |||||
Term loan, due January 1, 2018 (2.27%) | $ | 34.3 | $ | 34.9 | |||
Note payable, due December 31, 2019 | 0.2 | 0.2 | |||||
Credit Facility, due October 15, 2020 (1.00%) | 26.9 | 26.4 | |||||
Series A notes, due July 5, 2022 (3.67%) | 42.0 | 42.0 | |||||
Series B notes, due July 5, 2024 (3.82%) | 53.0 | 53.0 | |||||
Series C notes, due July 5, 2027 (4.02%) | 73.0 | 73.0 | |||||
229.4 | 229.5 | ||||||
Less: unamortized debt issuance costs | 0.8 | 0.9 | |||||
Total debt | 228.6 | 228.6 | |||||
Less: current portion of long-term debt | 34.4 | 2.4 | |||||
Long-term debt, net | $ | 194.2 | $ | 226.2 |
(in millions) | Sell | ||||||
Currency | Purchase | U. S. Dollar (“USD”) | Euro | ||||
USD | 51.5 | — | 48.1 | ||||
Yen | 5,752.0 | 33.1 | 16.8 | ||||
Singapore Dollar | 35.6 | 17.2 | 7.4 |
Amount of Gain (Loss) Recognized in OCI for the | Amount of Loss (Gain) Reclassified from Accumulated OCI into Income for the | Location of Loss (Gain) Reclassified from Accumulated OCI into Income | |||||||||||||||
Three Months Ended March 31, | Three Months Ended March 31, | ||||||||||||||||
($ in millions) | 2017 | 2016 | 2017 | 2016 | |||||||||||||
Cash Flow Hedges: | |||||||||||||||||
Foreign currency hedge contracts | $ | 0.3 | $ | (0.6 | ) | $ | 0.1 | $ | — | Net sales | |||||||
Foreign currency hedge contracts | 1.1 | (0.2 | ) | — | — | Cost of goods and services sold | |||||||||||
Interest rate swap contracts | — | (0.2 | ) | 0.1 | 0.2 | Interest expense | |||||||||||
Forward treasury locks | — | — | 0.1 | 0.1 | Interest expense | ||||||||||||
Total | $ | 1.4 | $ | (1.0 | ) | $ | 0.3 | $ | 0.3 | ||||||||
Net Investment Hedges: | |||||||||||||||||
Foreign currency-denominated debt | $ | (0.3 | ) | $ | (1.1 | ) | $ | — | $ | — | Other expense | ||||||
Total | $ | (0.3 | ) | $ | (1.1 | ) | $ | — | $ | — |
• | Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. |
• | Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. |
• | Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. |
Balance at | Basis of Fair Value Measurements | ||||||||||||||
($ in millions) | March 31, 2017 | Level 1 | Level 2 | Level 3 | |||||||||||
Assets: | |||||||||||||||
Deferred compensation assets | $ | 7.5 | $ | 7.5 | $ | — | $ | — | |||||||
Foreign currency contracts | 1.6 | — | 1.6 | — | |||||||||||
$ | 9.1 | $ | 7.5 | $ | 1.6 | $ | — | ||||||||
Liabilities: | |||||||||||||||
Contingent consideration | $ | 8.2 | $ | — | $ | — | $ | 8.2 | |||||||
Deferred compensation liabilities | 8.9 | 8.9 | — | — | |||||||||||
Interest rate swap contract | 0.7 | — | 0.7 | — | |||||||||||
Foreign currency contracts | 0.1 | — | 0.1 | — | |||||||||||
$ | 17.9 | $ | 8.9 | $ | 0.8 | $ | 8.2 |
Balance at | Basis of Fair Value Measurements | ||||||||||||||
($ in millions) | December 31, 2016 | Level 1 | Level 2 | Level 3 | |||||||||||
Assets: | |||||||||||||||
Deferred compensation assets | $ | 7.4 | $ | 7.4 | $ | — | $ | — | |||||||
Foreign currency contracts | 0.2 | — | 0.2 | — | |||||||||||
$ | 7.6 | $ | 7.4 | $ | 0.2 | $ | — | ||||||||
Liabilities: | |||||||||||||||
Contingent consideration | $ | 8.0 | $ | — | $ | — | $ | 8.0 | |||||||
Deferred compensation liabilities | 8.4 | 8.4 | — | — | |||||||||||
Interest rate swap contract | 1.0 | — | 1.0 | — | |||||||||||
Foreign currency contracts | 1.6 | — | 1.6 | — | |||||||||||
$ | 19.0 | $ | 8.4 | $ | 2.6 | $ | 8.0 |
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Beginning balance | $ | 8.0 | $ | 6.0 | |||
Increase in fair value recorded in earnings | 0.3 | 0.2 | |||||
Payments | (0.1 | ) | — | ||||
Ending balance | $ | 8.2 | $ | 6.2 |
Pension benefits | Other retirement benefits | Total | |||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | 2017 | 2016 | ||||||||||||||||||
Service cost | $ | 2.7 | $ | 2.7 | $ | — | $ | 0.1 | $ | 2.7 | $ | 2.8 | |||||||||||
Interest cost | 2.5 | 2.6 | 0.1 | 0.1 | 2.6 | 2.7 | |||||||||||||||||
Expected return on assets | (3.4 | ) | (3.2 | ) | — | — | (3.4 | ) | (3.2 | ) | |||||||||||||
Amortization of prior service credit | (0.3 | ) | (0.3 | ) | (0.2 | ) | — | (0.5 | ) | (0.3 | ) | ||||||||||||
Recognized actuarial losses (gains) | 1.2 | 1.1 | (0.7 | ) | (0.3 | ) | 0.5 | 0.8 | |||||||||||||||
Net periodic benefit cost | $ | 2.7 | $ | 2.9 | $ | (0.8 | ) | $ | (0.1 | ) | $ | 1.9 | $ | 2.8 |
Pension benefits | Other retirement benefits | Total | |||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | 2017 | 2016 | ||||||||||||||||||
U.S. plans | $ | 2.0 | $ | 2.3 | $ | (0.8 | ) | $ | (0.1 | ) | $ | 1.2 | $ | 2.2 | |||||||||
International plans | 0.7 | 0.6 | — | — | 0.7 | 0.6 | |||||||||||||||||
Net periodic benefit cost | $ | 2.7 | $ | 2.9 | $ | (0.8 | ) | $ | (0.1 | ) | $ | 1.9 | $ | 2.8 |
($ in millions) | Losses on cash flow hedges | Unrealized gains on investment securities | Defined benefit pension and other postretirement plans | Foreign currency translation | Total | ||||||||||||||
Balance, December 31, 2016 | $ | (3.2 | ) | $ | 5.2 | $ | (45.4 | ) | $ | (143.4 | ) | $ | (186.8 | ) | |||||
Other comprehensive income (loss) before reclassifications | 1.4 | 0.3 | (0.1 | ) | 5.9 | 7.5 | |||||||||||||
Amounts reclassified out | 0.3 | — | — | — | 0.3 | ||||||||||||||
Other comprehensive income (loss), net of tax | 1.7 | 0.3 | (0.1 | ) | 5.9 | 7.8 | |||||||||||||
Balance, March 31, 2017 | $ | (1.5 | ) | $ | 5.5 | $ | (45.5 | ) | $ | (137.5 | ) | $ | (179.0 | ) |
Three Months Ended March 31, | Location on Statement of Income | ||||||||
Detail of components | 2017 | 2016 | |||||||
Losses on cash flow hedges: | |||||||||
Foreign currency contracts | $ | (0.1 | ) | $ | — | Net sales | |||
Interest rate swap contracts | (0.2 | ) | (0.3 | ) | Interest expense | ||||
Forward treasury locks | (0.1 | ) | (0.1 | ) | Interest expense | ||||
Total before tax | (0.4 | ) | (0.4 | ) | |||||
Tax expense | 0.1 | 0.1 | |||||||
Net of tax | $ | (0.3 | ) | $ | (0.3 | ) | |||
Amortization of defined benefit pension and other postretirement plans: | |||||||||
Prior service credit | $ | 0.5 | $ | 0.3 | (a) | ||||
Actuarial losses | (0.5 | ) | (0.8 | ) | (a) | ||||
Total before tax | — | (0.5 | ) | ||||||
Tax expense | — | 0.2 | |||||||
Net of tax | $ | — | $ | (0.3 | ) | ||||
Total reclassifications for the period, net of tax | $ | (0.3 | ) | $ | (0.6 | ) |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Restructuring and related charges: | |||||||
Severance and post-employment benefits | $ | — | $ | 7.9 | |||
Asset-related charges | — | 15.0 | |||||
Total restructuring and related charges | — | 22.9 | |||||
Venezuela currency devaluation | — | 2.7 | |||||
Development income | (0.4 | ) | (0.4 | ) | |||
Contingent consideration costs | 0.3 | 0.2 | |||||
Other items | 1.0 | 0.4 | |||||
Total other expense | $ | 0.9 | $ | 25.8 |
($ in millions) | Severance and benefits | Asset-related charges | Other charges | Total | ||||||||
Balance, December 31, 2016 | $ | 5.9 | $ | — | $ | — | $ | 5.9 | ||||
Charges | — | — | — | — | ||||||||
Cash payments | (1.1 | ) | — | — | (1.1 | ) | ||||||
Non-cash asset write-downs | — | — | — | — | ||||||||
Balance, March 31, 2017 | $ | 4.8 | $ | — | $ | — | $ | 4.8 |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Net sales: | |||||||
Proprietary Products | $ | 308.8 | $ | 290.8 | |||
Contract-Manufactured Products | 79.1 | 71.6 | |||||
Intersegment sales elimination | (0.2 | ) | (0.3 | ) | |||
Consolidated net sales | $ | 387.7 | $ | 362.1 | |||
Operating profit (loss): | |||||||
Proprietary Products | $ | 64.9 | $ | 61.9 | |||
Contract-Manufactured Products | 8.8 | 7.0 | |||||
Corporate | (12.4 | ) | (13.3 | ) | |||
Other unallocated items | — | (25.6 | ) | ||||
Total operating profit | $ | 61.3 | $ | 30.0 | |||
Interest expense | 2.1 | 2.5 | |||||
Interest income | 0.3 | 0.3 | |||||
Income before income taxes | $ | 59.5 | $ | 27.8 |
Three Months Ended March 31, | % Change | ||||||||||||
($ in millions) | 2017 | 2016 | As-Reported | Ex-Currency | |||||||||
Proprietary Products | $ | 308.8 | $ | 290.8 | 6.2 | % | 8.0 | % | |||||
Contract-Manufactured Products | 79.1 | 71.6 | 10.6 | % | 11.4 | % | |||||||
Intersegment sales elimination | (0.2 | ) | (0.3 | ) | — | — | |||||||
Consolidated net sales | $ | 387.7 | $ | 362.1 | 7.1 | % | 8.7 | % |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Proprietary Products: | |||||||
Gross Profit | $ | 121.2 | $ | 112.8 | |||
Gross Profit Margin | 39.2 | % | 38.8 | % | |||
Contract-Manufactured Products: | |||||||
Gross Profit | $ | 12.9 | $ | 10.5 | |||
Gross Profit Margin | 16.3 | % | 14.7 | % | |||
Consolidated Gross Profit | $ | 134.1 | $ | 123.3 | |||
Consolidated Gross Profit Margin | 34.6 | % | 34.0 | % |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Proprietary Products | $ | 10.3 | $ | 9.4 | |||
Contract-Manufactured Products | — | — | |||||
Consolidated R&D Costs | $ | 10.3 | $ | 9.4 |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Proprietary Products | $ | 45.1 | $ | 41.0 | |||
Contract-Manufactured Products | 4.1 | 3.8 | |||||
Corporate | 12.4 | 13.3 | |||||
Consolidated SG&A costs | $ | 61.6 | $ | 58.1 | |||
SG&A as a % of net sales | 15.9 | % | 16.0 | % |
Expense (income) | Three Months Ended March 31, | ||||||
($ in millions) | 2017 | 2016 | |||||
Proprietary Products | $ | 1.0 | $ | 0.5 | |||
Contract-Manufactured Products | — | (0.3 | ) | ||||
Corporate | (0.1 | ) | — | ||||
Unallocated items | — | 25.6 | |||||
Consolidated other expense | $ | 0.9 | $ | 25.8 |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Proprietary Products | $ | 64.9 | $ | 61.9 | |||
Contract-Manufactured Products | 8.8 | 7.0 | |||||
Corporate | (12.4 | ) | (13.3 | ) | |||
Adjusted consolidated operating profit | $ | 61.3 | $ | 55.6 | |||
Adjusted consolidated operating profit margin | 15.8 | % | 15.4 | % | |||
Unallocated items | — | (25.6 | ) | ||||
Consolidated operating profit | $ | 61.3 | $ | 30.0 | |||
Consolidated operating profit margin | 15.8 | % | 8.3 | % |
Three Months Ended March 31, | |||||||
($ in millions) | 2017 | 2016 | |||||
Interest expense | $ | 2.7 | $ | 3.2 | |||
Capitalized interest | (0.6 | ) | (0.7 | ) | |||
Interest income | (0.3 | ) | (0.3 | ) | |||
Interest expense, net | $ | 1.8 | $ | 2.2 |
($ in millions) | 2017 | 2016 | |||||
Net cash provided by operating activities | $ | 20.7 | $ | 3.0 | |||
Net cash used in investing activities | $ | (34.7 | ) | $ | (38.6 | ) | |
Net cash used in financing activities | $ | (21.8 | ) | $ | (65.1 | ) |
($ in millions) | March 31, 2017 | December 31, 2016 | |||||
Cash and cash equivalents | $ | 169.4 | $ | 203.0 | |||
Working capital | $ | 396.1 | $ | 400.9 | |||
Total debt | $ | 228.6 | $ | 228.6 | |||
Total equity | $ | 1,168.6 | $ | 1,117.5 | |||
Net debt-to-total invested capital | 4.8 | % | 2.2 | % |
• | sales demand and our ability to meet that demand; |
• | competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability; |
• | customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them; |
• | the timing, regulatory approval and commercial success of customer products that incorporate our products and systems; |
• | whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems; |
• | the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Daikyo Crystal Zenith® prefilled syringes; |
• | average profitability, or mix, of products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings; |
• | maintaining or improving production efficiencies and overhead absorption; |
• | dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo; |
• | the loss of key personnel or highly-skilled employees; |
• | the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements; |
• | interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products; |
• | the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials; |
• | the cost and progress of development, regulatory approval and marketing of new products; |
• | our ability to obtain and maintain licenses in any jurisdiction in which we do business; |
• | the relative strength of USD in relation to other currencies, particularly the Euro, the Singapore Dollar, the Danish Krone, Yen, Venezuelan Bolivar, Colombian and Argentinian Peso, and Brazilian Real; and |
• | the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability. |
Period | Total number of shares purchased (1)(2)(3) | Average price paid per share (1)(2)(3) | Total number of shares purchased as part of publicly announced plans or programs (3) | Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (3) | |||||||||
January 1 – 31, 2017 | 1,777 | $ | 84.26 | — | 800,000 | ||||||||
February 1 – 28, 2017 | 130,095 | 84.84 | 75,000 | 725,000 | |||||||||
March 1 – 31, 2017 | 250,000 | 82.67 | 250,000 | 475,000 | |||||||||
Total | 381,872 | $ | 83.42 | 325,000 | 475,000 |
(1) | Includes 10,176 shares purchased on behalf of employees enrolled in the Non-Qualified Deferred Compensation Plan for Designated Employees (Amended and Restated Effective January 1, 2008). Under the plan, Company match contributions are delivered to the plan’s investment administrator, who then purchases shares in the open market and credits the shares to individual plan accounts. |
(2) | Includes 46,696 shares of common stock acquired from employees who tendered already-owned shares to satisfy the withholding tax obligations on the vesting of restricted stock awards, as part of the 2011 and 2016 Plans. |
(3) | In December 2016, we announced a share repurchase program authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The program commenced on January 1, 2017 and is expected to be completed by December 31, 2017. During the first quarter of 2017, we purchased 325,000 shares of our common stock under the program at a cost of $26.9 million, or an average price of $82.84 per share. |
Name | For | Against | Withheld/Abstain | Broker Non-Votes |
Mark A. Buthman | 64,532,664 | 70,042 | 93,747 | 2,636,369 |
William F. Feehery | 64,538,589 | 64,132 | 93,732 | 2,636,369 |
Eric M. Green | 63,865,364 | 737,783 | 93,306 | 2,636,369 |
Thomas W. Hofmann | 64,534,819 | 68,054 | 93,580 | 2,636,369 |
Paula A. Johnson | 32,515,415 | 17,110,568 | 15,070,470 | 2,636,369 |
Myla P. Lai-Goldman | 64,540,057 | 63,881 | 92,515 | 2,636,369 |
Douglas A. Michels | 63,880,477 | 722,229 | 93,747 | 2,636,369 |
Paolo Pucci | 55,876,981 | 7,118,812 | 1,700,660 | 2,636,369 |
John H. Weiland | 63,864,281 | 738,425 | 93,747 | 2,636,369 |
Patrick J. Zenner | 63,752,392 | 816,569 | 127,492 | 2,636,369 |
For | Against | Abstain | Broker Non-Votes |
61,921,308 | 2,626,714 | 148,431 | 2,636,369 |
Annual | Every 2 Years | Every 3 Years | Abstain | Broker Non-Votes |
58,013,162 | 18,296 | 6,544,179 | 120,816 | 2,636,369 |
For | Against | Abstain | Broker Non-Votes |
67,044,747 | 196,115 | 91,960 | Not applicable |
Exhibit # | Description |
3.1 | Our Amended and Restated Articles of Incorporation are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
3.2 | Our Bylaws, as amended through May 5, 2015, are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
4.1 | Form of stock certificate for common stock is incorporated by reference from our annual report on Form 10-K dated May 6, 1999. |
4.2 | Article 5, 6, 8(c) and 9 of our Amended and Restated Articles of Incorporation are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
4.3 | Article I and V of our Bylaws, as amended through May 5, 2015, are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
4.4 (1) | Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted. |
31.1 | Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 | Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1* | Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2* | Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
1. | I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
1. | I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Document and Entity Information |
3 Months Ended |
---|---|
Mar. 31, 2017
shares
| |
Document and Entity Information [Abstract] | |
Entity Registrant Name | WEST PHARMACEUTICAL SERVICES INC |
Entity Central Index Key | 0000105770 |
Current Fiscal Year End Date | --12-31 |
Entity Well-known Seasoned Issuer | Yes |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Filer Category | Large Accelerated Filer |
Entity Common Stock, Shares Outstanding | 73,553,655 |
Document Fiscal Year Focus | 2017 |
Document Fiscal Period Focus | Q1 |
Document Type | 10-Q |
Amendment Flag | false |
Document Period End Date | Mar. 31, 2017 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Income Statement [Abstract] | ||
Net sales | $ 387.7 | $ 362.1 |
Cost of goods and services sold | 253.6 | 238.8 |
Gross profit | 134.1 | 123.3 |
Research and development | 10.3 | 9.4 |
Selling, general and administrative expenses | 61.6 | 58.1 |
Other expense (Note 12) | 0.9 | 25.8 |
Operating profit | 61.3 | 30.0 |
Interest expense | 2.1 | 2.5 |
Interest income | 0.3 | 0.3 |
Income before income taxes | 59.5 | 27.8 |
Income tax expense | 2.2 | 6.9 |
Equity in net income of affiliated companies | 3.6 | 1.2 |
Net income | $ 60.9 | $ 22.1 |
Net income per share: | ||
Basic (in dollars per share) | $ 0.83 | $ 0.31 |
Diluted (in dollars per share) | $ 0.81 | $ 0.30 |
Weighted average shares outstanding: | ||
Basic (in shares) | 73.3 | 72.5 |
Diluted (in shares) | 74.9 | 74.1 |
Dividends declared per share | $ 0.13 | $ 0.12 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 60.9 | $ 22.1 |
Other comprehensive income (loss), net of tax: | ||
Foreign currency translation adjustments | 5.9 | 14.9 |
Defined benefit pension and other postretirement plan adjustments, net of tax of $(0.1) and $0.2 | (0.1) | 0.4 |
Net gain on investment securities, net of tax of $0.1 | 0.3 | 0.0 |
Net gain (loss) on derivatives, net of tax of $0.8 and $(0.2) | 1.7 | (0.7) |
Other comprehensive income, net of tax | 7.8 | 14.6 |
Comprehensive income | $ 68.7 | $ 36.7 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Statement of Comprehensive Income [Abstract] | ||
Defined benefit pension and other postretirement plan adjustments, tax | $ (0.1) | $ 0.2 |
Net gain on investment securities, tax | 0.1 | 0.0 |
Net gains on derivatives, tax | $ 0.8 | $ (0.2) |
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares shares in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Balance Sheet Related Disclosures [Abstract] | ||
Preferred stock, shares authorized (in shares) | 3.0 | 3.0 |
Preferred stock, shares issued (in shares) | 0.0 | 0.0 |
Preferred stock, shares outstanding (in shares) | 0.0 | 0.0 |
Common stock, par value (in dollars per share) | $ 0.25 | $ 0.25 |
Common stock, shares authorized (in shares) | 100.0 | 100.0 |
Common stock, shares issued (in shares) | 74.4 | 73.7 |
Common stock, shares outstanding (in shares) | 73.6 | 73.1 |
Treasury stock, at cost (in shares) | 0.8 | 0.6 |
Summary of Significant Accounting Policies |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March 31, 2017 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year. |
New Accounting Standards |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |
New Accounting Standards | New Accounting Standards Recently Adopted Standards In January 2017, the Financial Accounting Standards Board (“FASB”) issued guidance which removes the second step of the goodwill impairment test. A goodwill impairment charge will now be the amount by which a reporting unit's carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. In January 2017, the FASB issued guidance which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. In October 2016, the FASB issued guidance which requires companies to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. We adopted this guidance as of January 1, 2017, on a modified retrospective basis. As a result of the adoption, a cumulative-effect adjustment of $4.1 million was recorded within retained earnings in our condensed consolidated balance sheet as of January 1, 2017 for unamortized tax expense previously deferred and previously unrecognized deferred tax assets. In March 2016, the FASB issued guidance that simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We adopted this guidance as of January 1, 2017, on a prospective basis as it relates to the timing or recognition and classification of share-based compensation award-related income tax effects. For the three months ended March 31, 2017, we recorded a tax benefit of $15.9 million within income tax expense in our condensed consolidated statement of income. These tax benefits were recorded within capital in excess of par value in our condensed consolidated balance sheet in the prior-year period. Also per the amended guidance, we classified the $15.9 million of excess tax benefits within net cash provided by operating activities in our condensed consolidated statement of cash flows, rather than net cash used in financing activities, which included the excess tax benefits for the three months ended March 31, 2016. The amended guidance allows entities to account for award forfeitures as they occur, however, we have elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. We expect to record additional tax benefits throughout 2017. In March 2016, the FASB issued guidance that simplifies the transition to the equity method of accounting. This guidance eliminates the requirement to retroactively adopt the equity method of accounting when there is an increase in the level of ownership interest or degree of influence. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. In July 2015, the FASB issued guidance regarding the subsequent measurement of inventory. This guidance requires inventory measured using any method other than last-in, first-out or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value represents estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. Standards Issued Not Yet Adopted In March 2017, the FASB issued guidance on the presentation of net periodic pension and postretirement benefit cost (net benefit cost). The guidance requires the bifurcation of net benefit cost. The service cost component will be presented with other employee compensation costs in operating income (or capitalized in assets) and the other components will be reported separately outside of operations, and will not be eligible for capitalization. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on our financial statements. In November 2016, the FASB issued guidance on the classification and presentation of restricted cash in the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. As of March 31, 2017, we had no restricted cash. In August 2016, the FASB issued guidance to reduce the diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on our financial statements. In February 2016, the FASB issued guidance on the accounting for leases. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. We are currently evaluating the impact that this guidance will have on our financial statements. As of March 31, 2017, future minimum rental payments under non-cancelable operating leases were $65.8 million. In January 2016, the FASB issued guidance that addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. We believe that the adoption of this guidance will not have a material impact on our financial statements. In May 2014, the FASB issued guidance on the accounting for revenue from contracts with customers that will supersede most existing revenue recognition guidance, including industry-specific guidance. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the guidance requires enhanced disclosures regarding the nature, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The FASB subsequently issued additional clarifying standards to address issues arising from implementation of the new revenue recognition standard. This guidance is effective for interim and annual reporting periods beginning on or after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. Entities can choose to apply the guidance using either a full retrospective approach or a modified retrospective approach. We have made progress towards completion of our evaluation of the potential impact that the adoption of this guidance will have on our financial statements. |
Net Income Per Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income Per Share | Net Income Per Share The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
During the three months ended March 31, 2017 and 2016, there were 0.2 million and 0.6 million shares from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. In December 2016, we announced a share repurchase program authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The program commenced on January 1, 2017 and is expected to be completed by December 31, 2017. During the three months ended March 31, 2017, we purchased 325,000 shares of our common stock under the program at a cost of $26.9 million, or an average price of $82.84 per share. |
Inventories |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:
|
Affiliated Companies |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Affiliated Companies | Affiliated Companies At March 31, 2017 and December 31, 2016, the aggregate carrying amount of investments in equity-method affiliates was $67.9 million and $69.3 million, respectively, and the aggregate carrying amount of cost-method investments, for which fair value was not readily determinable, was $13.4 million at both period-ends. We test our cost-method investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. Please refer to Note 5, Affiliated Companies, to the consolidated financial statements in our 2016 Annual Report for additional details. |
Debt |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | Debt The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of December 31, 2016.
Please refer to Note 8, Debt, to the consolidated financial statements in our 2016 Annual Report for additional details regarding our debt agreements. At March 31, 2017, we had $26.9 million in outstanding long-term borrowings under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), of which $4.5 million was denominated in Japanese Yen (“Yen”) and $22.4 million was denominated in Euro. These borrowings, together with outstanding letters of credit of $3.0 million, resulted in an available borrowing capacity under the Credit Facility of $270.1 million at March 31, 2017. Please refer to Note 7, Derivative Financial Instruments, for a discussion of the foreign currency hedges associated with this facility. In addition, at March 31, 2017, we had $34.3 million outstanding under our five-year term loan due January 2018, all of which was classified as current. Please refer to Note 7, Derivative Financial Instruments, for a discussion of the interest-rate swap agreement associated with this loan. |
Derivative Financial Instruments |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Financial Instruments | Derivative Financial Instruments Our ongoing business operations expose us to various risks such as fluctuating interest rates, foreign exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments such as interest rate swaps, options and foreign exchange contracts for periods consistent with and for notional amounts equal to or less than the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value. Interest Rate Risk At March 31, 2017, we had a $34.3 million forward-start interest rate swap outstanding that hedges the variability in cash flows due to changes in the applicable interest rate of our variable-rate five-year term loan. Under this swap, we receive variable interest rate payments based on one-month London Interbank Offered Rate (“LIBOR”) plus a margin in return for making monthly fixed interest payments at 5.41%. We designated this swap as a cash flow hedge. Foreign Exchange Rate Risk In 2016 and 2015, we entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of March 31, 2017 and December 31, 2016, the total amount of these forward exchange contracts was €73.0 million and €57.5 million, respectively. In addition, in the fourth quarter of 2016, we entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of March 31, 2017, we had outstanding foreign currency contracts to purchase and sell certain currencies, as follows:
At March 31, 2017, a portion of our debt consisted of borrowings denominated in currencies other than USD. We have designated our €21.0 million ($22.4 million) Euro-denominated borrowings under our Credit Facility as a hedge of our net investment in certain European subsidiaries. A cumulative foreign currency translation gain of $1.4 million pre-tax ($0.9 million after tax) on this debt was recorded within accumulated other comprehensive loss as of March 31, 2017. We have also designated our ¥500.0 million ($4.5 million) Yen-denominated borrowings under our Credit Facility as a hedge of our net investment in Daikyo Seiko, Ltd. (“Daikyo”). At March 31, 2017, there was a cumulative foreign currency translation loss on this Yen-denominated debt of $0.3 million pre-tax ($0.2 million after tax), which was also included within accumulated other comprehensive loss. Commodity Price Risk Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception. In November 2016, we purchased a series of call options for a total of 96,525 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases through November 2017. With these contracts, we may benefit from an increase in crude oil prices, as there is no downward exposure other than the $0.2 million premium that we paid to purchase the contracts. During the three months ended March 31, 2017, the loss recorded in cost of goods and services sold related to these call options was $0.2 million. Effects of Derivative Instruments on Financial Position and Results of Operations Please refer to Note 8, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of March 31, 2017 and December 31, 2016. The following table summarizes the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings, net of tax:
For the three months ended March 31, 2017 and 2016, there was no material ineffectiveness related to our hedges. |
Fair Value Measurements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current assets and other current liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. Our interest rate swap, included within other long-term liabilities, is valued based on the terms of the contract and observable market inputs (i.e., LIBOR, Eurodollar synthetic forwards and swap spreads). Please refer to Note 7, Derivative Financial Instruments, for further discussion of our derivatives. Level 3 Fair Value Measurements The fair value of the contingent consideration liability related to the SmartDose technology platform (the “SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the contingent consideration liability. The following table provides a summary of changes in our Level 3 fair value measurements:
Other Financial Instruments We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At March 31, 2017, the estimated fair value of long-term debt was $196.8 million compared to a carrying amount of $194.2 million. At December 31, 2016, the estimated fair value of long-term debt was $228.3 million and the carrying amount was $226.2 million. |
Stock-Based Compensation |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock-Based Compensation | Stock-Based Compensation The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At March 31, 2017, there were 4,693,250 shares remaining in the 2016 Plan for future grants. During the three months ended March 31, 2017, we granted 418,528 stock options at a weighted average exercise price of $83.47 per share based on the grant-date fair value of our stock to key employees under the 2016 Plan. The weighted average grant date fair value of options granted was $17.94 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 2.05%; expected life of 5.9 years based on prior experience; stock volatility of 19.9% based on historical data; and a dividend yield of 0.7%. Stock option expense is recognized over the vesting period, net of forfeitures. During the three months ended March 31, 2017, we granted 86,597 performance share unit (“PSU”) awards at a weighted average grant-date fair value of $83.47 per share to key employees under the 2016 Plan. Each PSU award entitles the holder to one share of our common stock if the annual growth rate of revenue and return on invested capital targets are achieved over a three-year performance period. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. Total stock-based compensation expense was $3.5 million and $4.6 million for the three months ended March 31, 2017 and 2016, respectively. |
Benefit Plans |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benefit Plans | Benefit Plans The components of net periodic benefit cost for the three months ended March 31 were as follows ($ in millions):
During the three months ended March 31, 2017, we contributed $20.0 million to our U.S. qualified pension plan. |
Accumulated Other Comprehensive Loss |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2017:
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 10, Benefit Plans, for additional details. |
Other Expense |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Expense | Other Expense Other expense consists of:
Restructuring and Related Charges On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. During the three months ended March 31, 2016, we incurred $22.9 million in restructuring and related charges, consisting of $7.9 million for severance charges, $10.0 million for a non-cash asset write-down associated with the discontinued use of a trademark, and $5.0 million for non-cash asset write-downs associated with the discontinued use of a patent and certain equipment. During the year ended December 31, 2016, we incurred $26.4 million in restructuring and related charges, consisting of $8.9 million for severance charges, $10.0 million for a non-cash asset write-down associated with the discontinued use of a trademark, $7.3 million for non-cash asset write-downs associated with the discontinued use of a patent and certain equipment, and $0.2 million for other charges. The balance of the charges related to this plan will be recognized as incurred in 2017. The following table presents activity related to our restructuring obligations:
Other Items On February 17, 2016, the Venezuelan government announced a devaluation of the Bolivar, from the previously-prevailing official exchange rate of 6.3 Bolivars to USD to 10.0 Bolivars to USD, and streamlined the previous three-tiered currency exchange mechanism into a dual currency exchange mechanism. As a result, during the three months ended March 31, 2016, we recorded a $2.7 million charge. If there are further devaluations of the Bolivar or other changes in the currency exchange mechanisms in Venezuela in the future, a pre-tax charge of up to $15.0 million, or $0.12 to $0.15 per diluted share, for the potential deconsolidation of our Venezuelan subsidiary, could be required. We will continue to actively monitor the political and economic developments in Venezuela, particularly as we have recently experienced reduced access to USD controlled by the Venezuelan government. In addition, during both the three months ended March 31, 2017 and 2016, we recognized development income of $0.4 million within Proprietary Products, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. As of March 31, 2017, there was $14.0 million of unearned income related to this payment, of which $1.5 million was included in other current liabilities and $12.5 million was included in other long-term liabilities. The unearned income is being recognized as development income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. Contingent consideration costs represent changes in the fair value of the SmartDose contingent consideration. Please refer to Note 8, Fair Value Measurements, for additional details. Other items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, and miscellaneous income and charges. |
Income Taxes |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $2.2 million and $6.9 million for the three months ended March 31, 2017 and 2016, respectively, and the effective tax rate was 3.6% and 24.8%, respectively. The decrease in the effective tax rate for the three months ended March 31, 2017, as compared to the same period in 2016, reflects the impact of a tax benefit of $15.9 million associated with our adoption of the guidance issued by the FASB regarding share-based payment transactions. Please refer to Note 2, New Accounting Standards, for additional details. |
Commitments and Contingencies |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity. There have been no significant changes to the commitments and contingencies included in our 2016 Annual Report. |
Segment Information |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information | Segment Information Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment develops commercial, operational, and innovation strategies across our global network, with specific emphasis on product offerings to biotechnology, generics, and pharmaceutical customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The following table presents information about our reportable segments, reconciled to consolidated totals:
The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments. During the three months ended March 31, 2016, we recorded $22.9 million in restructuring and related charges, as well as a charge of $2.7 million related to the devaluation of the Venezuelan Bolivar from the previously-prevailing official exchange rate of 6.3 Bolivars to USD to 10.0 Bolivars to USD. Please refer to Note 12, Other Expense, for further discussion of these items. |
Summary of Significant Accounting Policies (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three months ended March 31, 2017 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year. |
New Accounting Standards | Recently Adopted Standards In January 2017, the Financial Accounting Standards Board (“FASB”) issued guidance which removes the second step of the goodwill impairment test. A goodwill impairment charge will now be the amount by which a reporting unit's carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. In January 2017, the FASB issued guidance which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. In October 2016, the FASB issued guidance which requires companies to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. We adopted this guidance as of January 1, 2017, on a modified retrospective basis. As a result of the adoption, a cumulative-effect adjustment of $4.1 million was recorded within retained earnings in our condensed consolidated balance sheet as of January 1, 2017 for unamortized tax expense previously deferred and previously unrecognized deferred tax assets. In March 2016, the FASB issued guidance that simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. We adopted this guidance as of January 1, 2017, on a prospective basis as it relates to the timing or recognition and classification of share-based compensation award-related income tax effects. For the three months ended March 31, 2017, we recorded a tax benefit of $15.9 million within income tax expense in our condensed consolidated statement of income. These tax benefits were recorded within capital in excess of par value in our condensed consolidated balance sheet in the prior-year period. Also per the amended guidance, we classified the $15.9 million of excess tax benefits within net cash provided by operating activities in our condensed consolidated statement of cash flows, rather than net cash used in financing activities, which included the excess tax benefits for the three months ended March 31, 2016. The amended guidance allows entities to account for award forfeitures as they occur, however, we have elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. We expect to record additional tax benefits throughout 2017. In March 2016, the FASB issued guidance that simplifies the transition to the equity method of accounting. This guidance eliminates the requirement to retroactively adopt the equity method of accounting when there is an increase in the level of ownership interest or degree of influence. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. In July 2015, the FASB issued guidance regarding the subsequent measurement of inventory. This guidance requires inventory measured using any method other than last-in, first-out or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value represents estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. We adopted this guidance as of January 1, 2017, on a prospective basis. The adoption did not have a material impact on our financial statements. Standards Issued Not Yet Adopted In March 2017, the FASB issued guidance on the presentation of net periodic pension and postretirement benefit cost (net benefit cost). The guidance requires the bifurcation of net benefit cost. The service cost component will be presented with other employee compensation costs in operating income (or capitalized in assets) and the other components will be reported separately outside of operations, and will not be eligible for capitalization. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on our financial statements. In November 2016, the FASB issued guidance on the classification and presentation of restricted cash in the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. As of March 31, 2017, we had no restricted cash. In August 2016, the FASB issued guidance to reduce the diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on our financial statements. In February 2016, the FASB issued guidance on the accounting for leases. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. We are currently evaluating the impact that this guidance will have on our financial statements. As of March 31, 2017, future minimum rental payments under non-cancelable operating leases were $65.8 million. In January 2016, the FASB issued guidance that addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. We believe that the adoption of this guidance will not have a material impact on our financial statements. In May 2014, the FASB issued guidance on the accounting for revenue from contracts with customers that will supersede most existing revenue recognition guidance, including industry-specific guidance. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the guidance requires enhanced disclosures regarding the nature, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The FASB subsequently issued additional clarifying standards to address issues arising from implementation of the new revenue recognition standard. This guidance is effective for interim and annual reporting periods beginning on or after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. Entities can choose to apply the guidance using either a full retrospective approach or a modified retrospective approach. We have made progress towards completion of our evaluation of the potential impact that the adoption of this guidance will have on our financial statements. |
Net Income Per Share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Basic to Diluted Net Income Per Share | The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
|
Inventories (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:
|
Debt (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt Obligations, Net of Current Maturities | The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of December 31, 2016.
|
Derivative Financial Instruments (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign Currency Contracts | As of March 31, 2017, we had outstanding foreign currency contracts to purchase and sell certain currencies, as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings | The following table summarizes the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings, net of tax:
|
Fair Value Measurements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assets and Liabilities Measured at Fair Value | The following tables present the assets and liabilities recorded at fair value on a recurring basis:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Changes in Level 3 Fair Value Measurements | The following table provides a summary of changes in our Level 3 fair value measurements:
|
Benefit Plans (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Net Periodic Benefit Cost | The components of net periodic benefit cost for the three months ended March 31 were as follows ($ in millions):
|
Accumulated Other Comprehensive Loss (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Accumulated Other Comprehensive Loss | The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2017:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification out of Accumulated Other Comprehensive Loss | A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 10, Benefit Plans, for additional details. |
Other Expense (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other Expense | Other expense consists of:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve | The following table presents activity related to our restructuring obligations:
|
Segment Information (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information | The following table presents information about our reportable segments, reconciled to consolidated totals:
|
Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Earnings Per Share [Abstract] | |||
Net income | $ 60.9 | $ 22.1 | |
Weighted average common shares outstanding (in shares) | 73,300,000 | 72,500,000 | |
Dilutive effect of stock options, stock appreciation rights and performance share awards, based on the treasury stock method (in shares) | 1,600,000 | 1,600,000 | |
Weighted average shares assuming dilution (in shares) | 74,900,000 | 74,100,000 | |
Antidilutive options excluded from computation of diluted net income per share (in shares) | 200,000 | 600,000 | |
Stock repurchase program, shares authorized | 800,000 | ||
Stock repurchase program, shares purchased | 325,000 | ||
Stock repurchase program, cost of shares purchased | $ 26.9 | ||
Stock repurchase program, average price per share | $ 82.84 |
Inventories (Details) - USD ($) $ in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 81.7 | $ 78.0 |
Work in process | 33.0 | 28.9 |
Finished goods | 97.6 | 92.4 |
Total inventories | $ 212.3 | $ 199.3 |
Affiliated Companies (Details) - USD ($) $ in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Equity Method Investments and Joint Ventures [Abstract] | ||
Carrying amount, equity-method investments | $ 67.9 | $ 69.3 |
Carrying amount, cost-method investments | $ 13.4 | $ 13.4 |
Fair Value Measurements (Details) - USD ($) $ in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Assets: | ||
Deferred compensation assets | $ 7.5 | $ 7.4 |
Foreign currency contracts | 1.6 | 0.2 |
Total assets at fair value | 9.1 | 7.6 |
Liabilities: | ||
Contingent consideration | 8.2 | 8.0 |
Deferred compensation liabilities | 8.9 | 8.4 |
Interest rate swap contracts | 0.7 | 1.0 |
Foreign currency contracts | 0.1 | 1.6 |
Total liabilities at fair value | 17.9 | 19.0 |
Level 1 [Member] | ||
Assets: | ||
Deferred compensation assets | 7.5 | 7.4 |
Total assets at fair value | 7.5 | 7.4 |
Liabilities: | ||
Deferred compensation liabilities | 8.9 | 8.4 |
Total liabilities at fair value | 8.9 | 8.4 |
Level 2 [Member] | ||
Assets: | ||
Foreign currency contracts | 1.6 | 0.2 |
Total assets at fair value | 1.6 | 0.2 |
Liabilities: | ||
Interest rate swap contracts | 0.7 | 1.0 |
Foreign currency contracts | 0.1 | 1.6 |
Total liabilities at fair value | 0.8 | 2.6 |
Level 3 [Member] | ||
Liabilities: | ||
Contingent consideration | 8.2 | 8.0 |
Total liabilities at fair value | $ 8.2 | $ 8.0 |
Fair Value Measurements Level 3 (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
Level 3 Fair Value Measurements [Roll Forward] | ||
Balance, beginning of period | $ 8.0 | $ 6.0 |
Increase in fair value recorded in earnings | 0.3 | 0.2 |
Payments | (0.1) | 0.0 |
Balance, end of period | $ 8.2 | $ 6.2 |
Fair Value Measurements Other Financial Instruments (Details) - USD ($) $ in Millions |
Mar. 31, 2017 |
Dec. 31, 2016 |
---|---|---|
Other Financial Instruments [Abstract] | ||
Long-term debt, fair value | $ 196.8 | $ 228.3 |
Long-term debt | $ 194.2 | $ 226.2 |
Other Expense (Details) - USD ($) $ in Millions |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Other Income and Expenses [Abstract] | |||
Severance and post-employment benefits | $ 0.0 | $ 7.9 | $ 8.9 |
Asset-related charges | 0.0 | 15.0 | |
Total restructuring and related charges | 0.0 | 22.9 | |
Venezuela currency devaluation | 0.0 | 2.7 | |
Development income | (0.4) | (0.4) | |
Contingent consideration costs | 0.3 | 0.2 | |
Other items | 1.0 | 0.4 | |
Total other expense | $ 0.9 | $ 25.8 |
Other Expense Items (Details) $ / shares in Units, $ in Millions |
3 Months Ended | ||||
---|---|---|---|---|---|
Mar. 31, 2017
USD ($)
$ / shares
|
Mar. 31, 2016
USD ($)
$ / shares
|
Dec. 31, 2016 |
Feb. 17, 2016 |
Jun. 30, 2013
USD ($)
|
|
Other Income and Expenses [Abstract] | |||||
Development income | $ (0.4) | $ (0.4) | |||
Nonrefundable payment from customer | 14.0 | $ 20.0 | |||
Unearned income, current | 1.5 | ||||
Unearned income, noncurrent | $ 12.5 | ||||
Summary of Investment Holdings [Line Items] | |||||
Earnings Per Share, Diluted | $ / shares | $ 0.81 | $ 0.30 | |||
Venezuela currency devaluation | $ 0.0 | $ 2.7 | |||
VENEZUELA | |||||
Summary of Investment Holdings [Line Items] | |||||
Foreign currency exchange rate, remeasurement | 6.3 | 10.0 | |||
Estimate of possible pre-tax charge | $ 15.0 | ||||
Minimum [Member] | VENEZUELA | |||||
Summary of Investment Holdings [Line Items] | |||||
Earnings Per Share, Diluted | $ / shares | $ 0.12 | ||||
Maximum [Member] | VENEZUELA | |||||
Summary of Investment Holdings [Line Items] | |||||
Earnings Per Share, Diluted | $ / shares | $ 0.15 |
Other Expense Restructuring and Related Charges (Details) - USD ($) $ in Millions |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
Restructuring Cost and Reserve [Line Items] | |||
Severance charges | $ 0.0 | $ 7.9 | $ 8.9 |
Asset impairment charges, trademark | 10.0 | 10.0 | |
Asset impairment charges, patent and equipment | 5.0 | 7.3 | |
Other restructuring costs | 0.2 | ||
Restructuring and related charges | 22.9 | 26.4 | |
Restructuring Reserve [Roll Forward] | |||
Balance, December 31, 2016 | 5.9 | ||
Charges | 0.0 | $ 22.9 | |
Cash payments | (1.1) | ||
Non-cash asset-write-downs | 0.0 | ||
Balance, March 31, 2017 | 4.8 | 5.9 | |
Severance and benefits [Member] | |||
Restructuring Reserve [Roll Forward] | |||
Balance, December 31, 2016 | 5.9 | ||
Charges | 0.0 | ||
Cash payments | (1.1) | ||
Non-cash asset-write-downs | 0.0 | ||
Balance, March 31, 2017 | 4.8 | 5.9 | |
Asset-Related Charges [Member] | |||
Restructuring Reserve [Roll Forward] | |||
Balance, December 31, 2016 | 0.0 | ||
Charges | 0.0 | ||
Cash payments | 0.0 | ||
Non-cash asset-write-downs | 0.0 | ||
Balance, March 31, 2017 | 0.0 | 0.0 | |
Asset-related charges [Member] | |||
Restructuring Reserve [Roll Forward] | |||
Balance, December 31, 2016 | 0.0 | ||
Charges | 0.0 | ||
Cash payments | 0.0 | ||
Non-cash asset-write-downs | 0.0 | ||
Balance, March 31, 2017 | $ 0.0 | $ 0.0 |
Income Taxes (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
|
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Tax expense (benefit) | $ 2.2 | $ 6.9 |
Effective tax rate | 3.60% | 24.80% |
Accounting Standards Update 2016-09 [Member] | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Tax expense (benefit) | $ (15.9) |
Segment Information (Details) $ in Millions |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2017
USD ($)
segment
|
Mar. 31, 2016
USD ($)
|
Dec. 31, 2016
USD ($)
|
|
Segment Reporting [Abstract] | |||
Number of reportable segments | segment | 2 | ||
Restructuring and related charges | $ 22.9 | $ 26.4 | |
Venezuela currency devaluation | $ 0.0 | 2.7 | |
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Net sales | 387.7 | 362.1 | |
Total operating (loss) profit | 61.3 | 30.0 | |
Interest expense | 2.1 | 2.5 | |
Interest income | 0.3 | 0.3 | |
Income before income taxes | 59.5 | 27.8 | |
Proprietary Products [Member] | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Net sales | 308.8 | 290.8 | |
Total operating (loss) profit | 64.9 | 61.9 | |
Contract-Manufactured Products [Member] | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Net sales | 79.1 | 71.6 | |
Total operating (loss) profit | 8.8 | 7.0 | |
Intersegment sales elimination [Member] | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Net sales | (0.2) | (0.3) | |
Corporate [Member] | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating (loss) profit | (12.4) | (13.3) | |
Other unallocated items [Member] | |||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||
Total operating (loss) profit | $ 0.0 | $ (25.6) |
&UL?5/1;IPP$/P5RQ\0 U,$9VQ%O//)6^^]YCQ)
M4G8-0A/F-&+X O..8%Y]#L'70ISX)SJ_7>=O5U/<1OYV&7[_=5U@MRJPBP*[
MA<#^\*'$SQ">\ \QV**G&DP=I\F2 OLV3O+".P_L77Q$]@X?I_VG,+5L+;F@
M\R\;^U\A.O"I;&[\"#7^@\V&@LJ%XZT_FW',1L-A-_T@-G_C_#]02P,$%
M @ N7VE2LIWN^BW 0 TP, !D !X;"]W;W)K RN_,SU/H?MA@*:A>.1W\VTYQ-AL-^_D)L^%7U!+ P04
M" "Y?:5*$YS\BL,! X! &0 'AL+W=O?;! E9LEMKF
M2/^^MB&$MC0OV+O,S,[:ZVQ$\V1; $>>M>IL3EOG^B-CMFQ!"WN#/73^3XU&
M"^=#TS#;&Q!5)&G%>)*\9UK(CA99S)U-D>'@E.S@;(@=M!;FUPD4CCG=T9?$
M@VQ:%Q*LR'K1P#=PW_NS\1%;5"JIH;,2.V*@SNG=[GA* SX"?D@8[6I/0B<7
MQ*<0?*YRF@1#H*!T04'XY0KWH%00\C9^SIIT*1F(Z_V+^L?8N^_E(BS^M^>'[%+([^+ZE>N$8M_3V?_-WWBA
MX"T3%6,GBJ;[]7:71HI2>U%4RNR]O^95=[UJ_Q]FV(!J WHS(/&H =,&[-,@
M&C6(M$'T:9!TL]6GTLW--I/9>EF+JU?WK_>